Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 15;16(1):734.
doi: 10.1186/s12885-016-2766-3.

Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

André Hennigs  1 , Fabian Riedel  1 , Adam Gondos  2 , Peter Sinn  3 , Peter Schirmacher  3 , Frederik Marmé  1   4 , Dirk Jäger  4 , Hans-Ulrich Kauczor  5 , Anne Stieber  5 , Katja Lindel  5 , Jürgen Debus  5 , Michael Golatta  1 , Florian Schütz  1 , Christof Sohn  1 , Jörg Heil  6 , Andreas Schneeweiss  7
Affiliations

Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

André Hennigs et al. BMC Cancer. .

Abstract

Background: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU.

Methods: The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral, non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and relative overall survival (ROS).

Results: Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 % (95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8; 83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2).

Conclusions: Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over 5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor, thus necessitating more intensified research and care.

Keywords: Breast cancer; Breast care unit; Molecular subtypes; Outcome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
LCR, ROS, OS, DDFS and DFS-whole invasive cohort. Kaplan-Meier survival plot for LCR, ROS, OS, DDFS, and DFS for the cohort of invasive cases. Shown are annual survival rates. The table presents the effective sample size for each interval. [LCR: local recurrence rate; DFS: disease-free survival; DDFS: distant disease-free survival; OS: observed overall survival; ROS: relative overall survival]
Fig. 2
Fig. 2
Overall Survival for Subtypes. Kaplan-Meier survival plot for overall survival according to molecular subtype (of invasive cancer). The annual survival rates for the following subtypes are shown: LumA, LumB/HER2 neg., LumB/HER2 pos., HER2, and Triple negative (TN). The table presents the effective sample size for each interval
See this image and copyright information in PMC

References

    1. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2013;64(1):52–62. doi: 10.3322/caac.21203. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group [EBCTCG] Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi: 10.1016/S0140-6736(05)66544-0. - DOI - PubMed
    1. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi: 10.1038/nature11412. - DOI - PMC - PubMed
    1. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Can Discov. 2013;3(1):27–34. doi: 10.1158/2159-8290.CD-12-0462. - DOI - PMC - PubMed
    1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi: 10.1038/35021093. - DOI - PubMed

MeSH terms